

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Beijing Chunlizhengda Medical Instruments Co., Ltd.*** (北京市春立正達醫療器械股份有限公司), you should at once hand this circular together with the accompanying form of proxy to the purchaser or transferee or to the bank, licensed securities dealer or registered institution in securities or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

**RESOLUTION REGARDING CHANGE OF CERTAIN
A SHARE PROCEEDS-FUNDED PROJECTS
AND
NOTICE OF THE EGM**

The EGM will be held at 2:00 p.m. on Tuesday, 10 October 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC.

A form of proxy for use at the EGM is enclosed and is also published on the website of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the website of the Company (<http://www.clzd.com>). If you intend to appoint a proxy to attend the EGM, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the EGM or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending the EGM and voting in person if you so wish.

* For identification purposes only

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
APPENDIX I — RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS	6
NOTICE OF THE EGM	17

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms shall have the following meanings:

“A Share(s)”	the ordinary share(s) issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for or credited as paid in RMB and are listed for trading on the Science and Technology Innovation Board of Shanghai Stock Exchange;
“Articles of Association”	the articles of association of the Company currently in force;
“Board”	the board of Directors;
“Company”	Beijing Chunlizhengda Medical Instruments Co., Ltd.*, a joint stock limited company incorporated in the PRC with limited liability, with A shares listed on the Science and Technology Innovation Board of Shanghai Stock Exchange and H Shares listed on the Main Board of the Hong Kong Stock Exchange;
“Director(s)”	the director(s) of the Company;
“EGM” or “Extraordinary General Meeting”	the 2023 first extraordinary general meeting of the Company to be held at to be held at 2:00 p.m. on Tuesday, 10 October 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC;
“H Share(s)”	overseas listed foreign share(s) with a nominal value of RMB1.00 each in the ordinary share capital of the Company, which are listed on the Main Board of the Hong Kong Stock Exchange;
“H Shareholder(s)”	the holder(s) of H Shares;
“Hong Kong”	the Hong Kong Special Administrative Region of PRC;
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited;
“Latest Practicable Date”	15 September 2023, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained in this circular;

DEFINITIONS

“Listing Rules”	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (as may be amended, modified or otherwise supplemented from time to time);
“PRC” or “China”	the People’s Republic of China, excluding, for the purpose of this circular only, Hong Kong, Macau Special Administrative Region, and Taiwan;
“RMB”	Renminbi, the lawful currency of PRC;
“Shanghai Stock Exchange”	the Shanghai Stock Exchange;
“Share(s)”	the A Share(s) and/or the H Share(s);
“Shareholder(s)”	the holder(s) of the Share(s).

If there is any inconsistency between the English and Chinese versions of this circular, the English version shall prevail.

* *For identification purpose only*



北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

Executive Directors:

Ms. Shi Wenling (*Chairman*)

Mr. Shi Chunbao

Ms. Yue Shujun

Mr. Xie Feng Bao

Registered Office and Headquarters in the PRC:

No.10 Xinmi Xi Er Road

Southern District of Tongzhou

Economic Development Zone

Tongzhou District

Beijing

the PRC

Postal Code: 101112

Non-executive Director:

Mr. Wang Xin

Independent Non-executive Directors:

Ms. Yao Lijie

Mr. Wong Tak Shing

Mr. Weng Jie

Principal Place of Business in Hong Kong:

20th Floor, Winbase Centre

208 Queen's Road Central

Sheung Wan

Hong Kong

To the Shareholders

Dear Sir or Madam,

**RESOLUTION REGARDING CHANGE OF CERTAIN
A SHARE PROCEEDS-FUNDED PROJECTS
AND
NOTICE OF THE EGM**

1. INTRODUCTION

Reference is made to the announcement of the Company dated 30 August 2023 in relation to the proposal to change of certain A Share proceeds-funded projects.

The purpose of this circular is to provide you with information on the proposal to change certain A Share proceeds-funded projects, and enable you to make informed decisions on whether to vote for or against the proposed ordinary resolution at the EGM.

2. PROPOSAL OF CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS

At the EGM, an ordinary resolution will be proposed to consider and, if thought fit, approve the change of certain A Share proceeds-funded projects, the full text of which is set out in Appendix I to this circular.

LETTER FROM THE BOARD

3. EGM

Notice convening the EGM to be held at 2:00 p.m. on Tuesday, 10 October 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC are set out on pages 17 to 18 of this circular and, together with the proxy form, have been published on the website of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the website of the Company (<http://www.clzd.com>) on 22 September 2023.

In order to be qualified to attend and vote at the EGM, holders of H shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by no later than 4:30 p.m. on Monday, 9 October 2023.

Holders of H Shares whose names appear on the Company's register of members for H Shares at the close of business on Monday, 9 October 2023 are entitled to attend and vote at the EGM.

A form of proxy for use at the EGM is enclosed and is also published on the website of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the website of the Company (<http://www.clzd.com>). If you intend to appoint a proxy to attend the EGM, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the EGM or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending the EGM and voting in person if you so wish.

As at the Latest Practicable Date, and to the best knowledge, belief and information of the Directors having made all reasonable enquiries, no Shareholder is required under the Listing Rules to abstain from voting on the proposed resolution at the EGM.

None of the Directors has any material interest in the resolution to be proposed at the EGM.

4. PROCEDURES FOR VOTING AT THE EGM

According to Rule 13.39(4) of the Listing Rules, the vote of Shareholders at the EGM will be taken by poll. Accordingly, all the resolution could be taken by poll at the EGM pursuant to the Articles of Association.

5. RECOMMENDATION

The Directors believe that the resolution mentioned above is in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that Shareholders vote in favour of the resolution to be proposed at the EGM as set out in the notice of the EGM.

LETTER FROM THE BOARD

6. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

By Order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC
22 September 2023

* *For identification purposes only*

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS

The details of the resolution regarding the change of certain A Share proceeds-funded projects are as follows:

References are made to the overseas regulatory announcement which sets out the A Share Prospectus for the Initial Public Offering and Listing of Shares of Beijing Chunlizhengda Medical Instruments Co., Ltd.* on the Science and Technology Innovation Board (《北京市春立正達醫療器械股份有限公司首次公開發行股票並在科創板上市招股說明書》) published by Beijing Chunlizhengda Medical Instruments Co., Ltd. on 27 December 2021 (“A Share Prospectus”), the circular of the Company (the “Circular”) dated 24 July 2020 and the announcement of the Company (the “Announcement”) dated 18 January 2022, in relation to, among others, the proposed amount of the proceeds from A Share Offering (“A Share Proceeds” or “Proceeds”), its proposed uses (“A Share Proceeds-funded Projects”) and certain adjustment to the amount of proceeds proposed to be invested in A Share Proceeds-funded Projects. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the A Share Prospectus, the Circular and the Announcement.

On 30 August 2023, the Company held the second meeting of the fifth session of the Board and the second meeting of the fifth session of the Supervisory Committee, at which the Resolution on the Change of Certain Proceeds-funded Projects (《關於部分募投項目變更的議案》) was considered and approved. The resolution approved the Company to make adjustments to certain A Share Proceeds-funded Projects. The independent Non-executive Directors of the Company expressed their explicit consent, and the sponsor, Huatai United Securities Co., Ltd. (hereinafter referred to as the “Sponsor”), issued verification opinions on this matter.

I. BASIC INFORMATION ON A SHARE PROCEEDS

As reviewed and approved by the listing committee of the Science and Technology Innovation Board of the Shanghai Stock Exchange, and pursuant to the document for the approval of registration Zheng Jian Xu Ke (2021) No. 3702 (證件許可(2021)3702號) issued by the China Securities Regulatory Commission, the Company issued 38,428,000 A Shares with a par value of RMB1 each, at the issue price of RMB29.81 per Share. The A Share Proceeds amounted to RMB1,145.5387 million in aggregate. The actual net A Share Proceeds amounted to RMB1,067.1283 million after deducting the issue expenses (exclusive of value-added tax). The payment of the A Share Proceeds mentioned above was verified by WUYIGE Certified Public Accountants LLP, and a Capital Verification Report (WUYIGE Yan Zi [2021] No. 3-00041) (大信驗字[2021]第3-00041號《驗資報告》) was issued by them.

The Company has deposited the A Share Proceeds in a special account. A supervision agreement on the special account for the Proceeds has also been entered into among the Company, the Sponsor and the relevant bank of the special account for the Proceeds in accordance with the applicable regulations. The supervision agreement clearly stipulates the relevant responsibilities and obligations of the Company, the Sponsor, and the relevant bank for the deposit of the Proceeds, clarifies the rights and obligations of all parties, and implements strict approval procedures for the use of the Proceeds to ensure the special funds are for specified purpose only.

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS
--

II. INFORMATION ON A SHARE PROCEEDS-FUNDED PROJECTS

As the actual net A Share Proceeds of the Company amounted to RMB1,067.1283 million, which was lower than the proposed amount of RMB2,000 million as disclosed in the A Share Prospectus and the Circular. With reference to the actual net Proceeds from the A Share Offering and the actual situation of A Share Proceeds-funded Projects, the Company adjusted the A Share Proceeds proposed to be invested in each of the A Share Proceeds-funded Projects. The specific adjustment allocation is as follows:

Unit: RMB0'000

No.	Name of Proceeds-funded Investment project	Total investment for the project	Amount of Proceeds to be invested before adjustment	Amount of Proceeds to be invested after adjustment
1	Integrated Construction Project of Orthopedic Implants and Supporting Materials	94,470.38	86,000.00	46,000.00
2	Research and Development ("R & D") Centre Construction Project	70,806.59	68,000.00	36,000.00
3	Marketing Network Construction Project	16,736.34	16,000.00	8,000.00
4	Replenishment of Working Capital Project	30,000.00	30,000.00	16,712.83
Total		<u>212,013.31</u>	<u>200,000.00</u>	<u>106,712.83</u>

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS
--

As of 30 June 2023, the A Share Proceeds-funded Projects and the use of the A Share Proceeds of the Company are as follows:

Unit: RMB0'000

No.	Name of Proceeds-funded Investment project	Total committed investment for the project	Total investment after adjustment	Accumulated amount invested as of the end of the period
1	Integrated Construction Project of Orthopedic Implants and Supporting Materials	86,000.00	46,000.00	11,985.86
2	R & D Centre Construction Project	68,000.00	36,000.00	4,660.94
3	Marketing Network Construction Project	16,000.00	8,000.00	102.27
4	Replenishment of Working Capital Project	<u>30,000.00</u>	<u>16,712.83</u>	<u>16,843.71</u>
Total		<u>200,000.00</u>	<u>106,712.83</u>	<u>33,592.77</u>

For details, please refer to the “Special Report on the Deposit and Actual Use of Proceeds for the First Half of 2023 of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (《北京市春立正達醫療器械股份有限公司2023年半年度募集資金存放與實際使用情況的專項報告》)” (Announcement No.: 2023-033) published by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 31 August 2023.

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS

III. DETAILS OF THE CHANGES AND ADJUSTMENTS TO CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS

(I) Adjustment to the investment amount of certain A Share Proceeds-funded Projects

Unit: RMB0'000

No.	Name of investment project in respect of the proceeds raised	Amount of Proceeds to be invested before adjustment	Amount of Proceeds to be invested after adjustment	Amount of change
1	R & D Centre Construction Project	36,000.00	42,000.00	+6,000.00
2	Marketing Network Construction Project	<u>8,000.00</u>	<u>2,000.00</u>	-6,000.00
Total		<u>44,000.00</u>	<u>44,000.00</u>	

(II) Changes and adjustments to the R & D Centre Construction Project

1. Adjustment to the investment amount of the R & D Centre Construction Project

Based on the actual situation of the Proceeds and taking into account the Company's need to further strengthen its forward-looking layout in the field of R & D, the Company intends to adjust the total amount of Proceeds to be used for the "R & D Centre Construction Project" from RMB360 million to RMB420 million, of which there will be an increase of RMB60 million, and the Company intends to deduct the increased funds from the Proceeds to be invested in the "Marketing Network Construction Project". The R & D Centre Construction Project is divided into the Beijing R & D Centre Construction Project and the Weixian R & D Centre Construction Project. The adjusted amount of RMB60 million will be fully invested in the Beijing R & D Centre Construction Project for the purposes of remuneration of R & D personnel and

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS
--

R & D expenses. There was no change in the specific R & D direction of the R & D Centre Construction Project after the change. Adjustments for changes in the R & D Centre Construction Project are as follows:

Unit: RMB0' 000

No.	Item	Before the change		After the change	
		Total investment	Proposed to be invested	Total investment	Proposed to be invested
I	Beijing R & D Project	15,063.39	10,800.00	21,063.39	16,800.00
1	R & D personnel remuneration	8,626.00	6,480.00	12,480.00	10,080.00
2	R & D expenses	6,437.39	4,320.00	6,437.39	6,720.00
II	Weixian R & D Centre Project	<u>55,743.20</u>	<u>25,200.00</u>	<u>55,743.20</u>	<u>25,200.00</u>
Total		<u>70,806.59</u>	<u>36,000.00</u>	<u>76,806.59</u>	<u>42,000.00</u>

2. *Analysis on the reasons for the change of R & D Centre Construction Project*

With the continuous expansion of the implementation of centralised procurement policies in the field of orthopedic consumables, improving the market competitiveness of products by strengthening product R & D and innovation capabilities is the key to adapting to industry changes and achieving sustainable development of the Company. Beijing, as an international exchange centre and a science and technology innovation centre, is gathered by colleges and universities and well-known hospitals, and has the geographical advantages and medical resource advantages of accessing cutting-edge technologies and advanced clinical experience at home and abroad. The Beijing R & D Project is committed to applying advanced technologies at home and abroad to actual products and improving existing products to enhance the sensitivity of products to market demand and ultimately enhance the Company's market competitiveness. Under the new industry policies and competition environment, in order to better promote the Beijing R & D Project, the Company intends to increase the total investment in projects and the total investment amount of Proceeds, so as to provide continuous and strong technical support for the Company's products and services and further enhance the Company's core competitiveness

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS
--

(III) Changes in Marketing Network Construction Project

1. *Adjustment to the total investment amount and Proceeds to be invested in Marketing Network Construction Project*

Based on the actual situation of the Proceeds and taking into account the Company’s need to further strengthen its forward-looking layout in the field of R & D, the Company intends to adjust the total project investment of the “Marketing Network Construction Project” from RMB80 million to RMB20 million, of which the Sub-project of marketing distribution outlets construction will no longer be invested, and the investment amount will be reduced by RMB60 million and invested in the “R & D Centre Construction Project”. The details of the adjustment of the total investment of the Marketing Network Construction Project and the Proceeds to be invested are as follows:

Unit: RMB0’ 000

No.	Item	Before the change		After the change	
		Total investment	Proposed to be invested	Total investment	Proposed to be invested
1	Marketing Training Centres	3,250.00	1,800.00	3,250.00	1,800.00
2	Marketing Distribution Outlets	12,978.34	6,000.00	0.00	0.00
3	Marketing Network Information System	500.00	200.00	200.00	200.00
Total		<u>16,736.34</u>	<u>8,000.00</u>	<u>3,750.00</u>	<u>2,000.00</u>

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS
--

2. *Changes in implementation methods and implementation locations*

The change is mainly due to the addition of online marketing training activities and marketing promotion activities for the implementation of the marketing training centre projects in the Marketing Network Construction Project according to the development and changes of the industry environment and the internal business development needs of the Company, and the relaxation of the implementation locations of the marketing training centres from 7 cities including Guangzhou, Shanghai, Chengdu, Wuhan, Zhengzhou, Shenyang and Xi'an to all provinces and prefecture-level cities in China. The details are as follows:

Name of the sub-project	Implementation method before change	Implementation method after change
Marketing Training Centres	Leasing sites to conduct marketing training activities	Leasing of venues or conducting marketing training and marketing promotion activities through online meetings
	Place of implementation before change	Place of implementation after change
	7 cities including Guangzhou, Shanghai, Chengdu, Wuhan, Zhengzhou, Shenyang and Xi'an	All provinces and their prefecture-level cities in China

3. *Analysis of reasons for changes in Marketing Network Construction Projects*

- (1) *Reasons for the adjustment of the total investment amount and Proceeds to be invested in the Marketing Network Construction Project*

With the continuous expansion of centralised procurement policies in the field of orthopedic consumables, the traditional marketing and promotion model of the medical device industry needs to adapt to the new policy environment and competition situation. The R & D capabilities and product quality of medical device manufacturers are also increasingly important in market promotion competition.

**APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN
A SHARE PROCEEDS-FUNDED PROJECTS**

In order to maintain the Company's product competitiveness and performance stability, as a listed company on the Science and Technology Innovation Board, the Company plans to further enrich the existing product layout and improve the product competitiveness by improving its R & D innovation ability.

The Company's Marketing Network Construction Project originally included three sub-projects, namely the marketing training centre construction, the marketing distribution outlets construction and the marketing network information system construction. Based on the above operating principles, the Company intends to reduce the total investment amount and the use of the Proceeds of the Marketing Network Construction Project as a whole, and increase the investment amount and the use of the Proceeds of the R & D Centre Construction Project to enhance the Company's R & D innovation capability.

For the marketing distribution outlets construction, with the gradual maturity of the modern logistics industry and the gradual improvement of the distribution and delivery network in various regions, the Company will make full use of the regional coverage capacity of existing distribution outlets, platform distributors and distributors to ensure the timeliness of product supply. For the marketing network information system construction project, the Company will further improve the existing reporting system and customer management methods and build additional system construction expenditures to achieve cost reduction and efficiency improvement. In the event of changes in industry policies, changes in the competitive environment and continuous improvement in the Company's performance in the future, the Company will consider resuming the construction of marketing delivery outlets and marketing network information system with its own funds in due course based on its actual operational needs.

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS
--

(2) *Reasons for the change in the implementation method and place of the Marketing Network Construction Project*

According to the development and changes of the industry environment and the internal business development needs of the Company, the Company increased the implementation methods of marketing training centre projects in the Marketing Network Construction Project to carry out online marketing training activities, mainly because with the increasing acceptance of video conferences and the maturity of technical means, the Company's marketing training activities were no longer limited to offline methods, but adopted more diversified and flexible methods to improve the efficiency of marketing promotion activities and reduce the cost of marketing promotion activities. Relaxation of the implementation locations of the marketing training centres from 7 cities, including Guangzhou, Shanghai, Chengdu, Wuhan, Zhengzhou, Shenyang and Xi'an, to all provinces and prefecture-level cities in China, mainly due to the nationwide distribution network and terminal hospitals served by the Company, the limitation of offline training locations to specific cities will cause inconvenience to some personnel participating in the training. In order to provide more flexible services to a wider range of distributors and clinicians, the specific implementation cities of marketing training activities are no longer restricted.

IV. IMPACT OF THE ADJUSTMENT TO THE INVESTMENT AMOUNT OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS ON THE DAILY OPERATION OF THE COMPANY

The internal adjustment to the investment amount of part of the A Share Proceeds-funded Projects is a prudent decision made by the Company based on the actual situation of the implementation of the relevant A Share Proceeds-funded Projects and the Company's own development strategy and actual operation needs. The internal adjustment of the investment amount of part of the A Share Proceeds-funded Projects will not have a substantial impact on the implemented projects and will be in line with the production and operation conditions of the Company at the current stage. The internal adjustment of the investment amount of part of the A Share Proceeds-funded Projects does not prejudice the interests of the Shareholders, is in compliance with the relevant requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange on the management of proceeds raised by listed companies, will not adversely affect the normal operation of the Company, will not prejudice the interests of the Shareholders, and is in line with the long-term development plan of the Company and the long-term interests of the Shareholders.

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS

V. STATEMENT OF SPECIAL OPINIONS

(I) Opinion of Independent Non-executive Directors

The independent Non-executive Directors of the Company are of the view that the adjustment and the change to certain A Share Proceeds-funded Projects is a prudent decision made by the Company based on the actual situation of the relevant A Share Proceeds-funded Projects and taking into account the Company's own development strategy and actual operation needs. It will not cause a substantial impact on the implemented projects and will be in line with the production and operation conditions of the Company at the current stage. The adjustment and the change to certain A Share Proceeds-funded Projects will not cause any material adverse impact on the normal operation of the Company, nor will it damage the interests of the Shareholders, which is in line with the long-term development plan of the Company and the long-term interests of the Shareholders. The decision-making and approval procedures of the matter are in compliance with the Regulatory Guideline for Listed Companies No. 2 – Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the Guideline No. 1 on the Application of Self-Regulatory Rules for Listed Companies on the Science and Technology Innovation Board of Shanghai Stock Exchange – Regulated Operation (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) and the Proceeds Management System (《募集資金管理制度》) of the company and other relevant laws, regulations, regulatory documents and the system of the Company. In conclusion, all independent Non-executive Directors approved the Resolution on the Change of Certain Proceeds-funded Projects.

(II) Opinion of the Supervisory Committee

The Supervisory Committee of the Company is of the view that the changes and adjustments of part of the A Share Proceeds-funded Projects are made by the Company in a prudent manner based on the actual situation of the relevant A Share Proceeds-funded Projects and taking into account the Company's own development strategy and actual operation needs. It will not have a substantial impact on the implemented projects and will be in line with the production and operation conditions of the Company at the current stage. The adjustment and the change to certain A Share Proceeds-funded Projects will not cause any material adverse impact on the normal operation of the Company, nor will it damage the interests of the Shareholders, which is in line with the long-term development plan of the Company and the long-term interests of the Shareholders. The decision-making and approval procedures of the matter are in compliance with the Regulatory Guideline for Listed Companies No. 2 – Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the Guideline No. 1 on the Application of Self-Regulatory Rules for Listed Companies on the Science and Technology Innovation Board of Shanghai Stock Exchange – Regulated Operation (《上海證券交易所科創板上市公司自律監管指

APPENDIX I RESOLUTION REGARDING CHANGE OF CERTAIN A SHARE PROCEEDS-FUNDED PROJECTS

引第1號－規範運作》) and the Proceeds Management System (《募集資金管理制度》) of the Company and other relevant laws, regulations, regulatory documents and the system of the Company. In conclusion, the Supervisory Committee approved the Resolution on the Change of Certain Proceeds-funded Projects.

(III) Verification Opinion of the Sponsor

The Sponsor is of the view that: the matters in relation to the adjustment and the change to certain A Share Proceeds-funded Projects of the Company have been considered and approved by the Board and the Supervisory Committee of the Company, and the independent Directors have expressed their explicit consent and shall be required the consideration and approval of the general meeting in the future. The necessary legal review procedures were performed in this stage. This matter is in compliance with the Regulatory Guideline for Listed Companies No. 2 – Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies (Revised in 2022) (《上市公司監管指引第2號－上市公司募集資金管理和使用的監管要求(2022年修訂)》), the Guideline No. 1 on the Application of Self-Regulatory Rules for Listed Companies on the Science and Technology Innovation Board of Shanghai Stock Exchange – Regulated Operation (《上海證券交易所科創板上市公司自律監管指引第1號－規範運作》), the Rules Governing the Listing of Shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange (《上海證券交易所科創板股票上市規則》), Measures for the Continuous Supervision of Companies Listed on the Science and Technology Innovation Board (for Trial Implementation) (《科創板上市公司持續監管辦法(試行)》) and other relevant laws and regulations. In conclusion, the Sponsor has no objection against the change of part of the A Share Proceeds-funded Projects of the Company.

The Resolution on the Change of Certain Proceeds-funded Projects will be proposed by way of ordinary resolution to be approved by the Shareholders at the EGM.

NOTICE OF THE EXTRAORDINARY GENERAL MEETING



北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

Notice is hereby given that the extraordinary general meeting (the “EGM”) of Beijing Chunlizhengda Medical Instruments Co., Ltd. (the “Company”) will be held at 2:00 p.m. on Tuesday, 10 October 2023 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC to consider and, if thought fit, to pass the following resolution. Unless otherwise defined, capitalized terms used in this notice shall have the same meanings as defined in the circular (the “Circular”) of the Company dated 22 September 2023.

ORDINARY RESOLUTION

1. To consider and approve the proposal of change of certain A Share proceeds-funded projects.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC
22 September 2023

* *For identification purposes only*

As at the date of this notice, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun, Ms. Shi Wenling and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Ms. Yao Lijie, Mr. Wong Tak Shing and Mr. Weng Jie.

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

Notes:

1. REGISTRATION OF MEMBERS

In order to be qualified to attend and vote at the EGM, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the office of the H Share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by no later than 4:30 p.m. on Monday, 9 October 2023.

Holders of H Shares whose names appear on the Company's register of members for H Shares at the close of business on Monday, 9 October 2023 are entitled to attend and vote at the EGM.

2. APPOINTMENT OF PROXY

Any Shareholder entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote at the meeting instead of him/her. A proxy need not be a Shareholder of the Company.

The instrument to appoint a proxy shall be in writing and signed by the Shareholder or of his/her attorney duly authorised in writing or, if the Shareholder is a corporate body, either executed under its common seal or signed by its legal representative, director or duly authorised attorney. If the proxy form is signed by the attorney of the Shareholder, the power of attorney or other authorisation document authorising the attorney to sign the proxy form must be notarised.

To be valid, the proxy form, together with the power of attorney or other authority (if any), shall be lodged by hand or post, to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for holders of H Shares) not less than 24 hours before the time appointed for holding the EGM or its adjourned meeting (as the case may be). Completion and return of the proxy form shall not preclude Shareholders from attending and voting in person at the EGM.

3. CONTACT INFORMATION OF THE COMPANY

Contact Person: Ms. Zhang Lili (張麗麗小姐)
Contact Tel: (8610) 8736 1998

4. PROCEDURES OF VOTING AT THE EGM

Pursuant to Rule 13.39(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, any vote of Shareholders at the EGM must be taken by poll.

5. OTHERS

The EGM is expected to take half a day. Shareholders attending the EGM (in person or by proxy) are responsible for their own transportation and accommodation fees. Identification documents must be shown by Shareholder(s) or proxies to attend the EGM.

Further details of the resolution are set out in the Circular.

This notice of EGM is despatched to the holders of H Shares only. The notice of EGM to the holders of A Shares is separately published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn/>).